cash money
Biotech

Biotech's top money raisers: 2025

While 2024 marked the return of the biotech megaround, 2025 proved that it wasn’t just a one-year anomaly.
Gabrielle Masson Mar 2, 2026 6:30am
two baskets of eggs on a farm

Boehringer axes MASH deal after OSE asset fails to show efficacy

Mar 2, 2026 2:16pm
How physiology powers biotech innovation

How physiology powers biotech innovation

Brought to you by American Physiological Society
stop train halt end road block railway

FDA demands ph. 3 trial of uniQure's Huntington's gene therapy

Mar 2, 2026 10:45am
Completing steps towards success checkmark on cubes symbolizing progress

Roche reports pivotal MS win, but deaths add to safety questions

Mar 2, 2026 6:00am
two arrows pointing different directions

Candid scores Nasdaq listing via reverse merger Rallybio

Mar 2, 2026 11:45am
More News

FDA fully releases clinical hold on Intellia CRISPR trials

Mar 2, 2026 10:55am

Cullgen ditches reverse merger with Pulmatrix to go with Gyre

Mar 2, 2026 10:55am

United Therapeutics' phase 3 win tees up filing to challenge J&J

Mar 2, 2026 10:40am

BioAtla lays off 70% of workforce, seeks buyers for antibodies

Mar 2, 2026 9:40am